Cross-Over Study to Evaluate the Efficacy of E-PR-01 on Activity Induced Joint Pain

A Randomized, Placebo-controlled, Double-blind, Cross-Over Study to Evaluate the Efficacy of E-PR-01 on Activity Induced Joint Pain

This Clinical trial study for the effect of a product E-PR-01 will be studied for its ability to attain rapid pain relief in the individuals suffering from exercise-induced knee joint pain, as well as determine its sustained effect on pain reduction over a treatment period of five days.

Study Overview

• Status: Completed
• Conditions: Joint Pain
• Intervention / Treatment: Other: E-PR-01; Other: E- PR-02

Detailed Description

The study is a randomized, double-blind, placebo controlled, cross-over study to explore the effect of a product E-PR-01 on joint pain. Approximately 50 participants aged between ≥ 20 and ≤ 60 years will be screened. At least 40 participants will be randomized, and the participants will be crossed over both the IP and placebo arms. A minimum of 32 participants must complete the study, after accounting for the screening failure and dropout /withdrawal rate of 20% each. The duration of each treatment for all the study participants will be 5 days, the washout period between each treatment period being 5 ± 2 days.

The total study period from the first start of treatment visit, inclusive of the washout and treatment periods, is estimated to be 15 days.

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• India
  • Maharashtra
    • Mumbai, Maharashtra, India, 400053
      • Vedic Lifesciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Physically active adults aged ≥20 and ≤60 years with history of knee joint pain aggravation on physical stress (walking, running, cycling etc.).
2. Body Mass Index (BMI) ≥ 20 and ≤ 29.9 kg/m2.
3. Participants with self-reported joint pain of ≥ 60 on 100 mm VAS scale after walking on treadmill using modified Naughton's protocol.
4. Participants with no or minimal pain at rest (≤ 30 mm on VAS scale).
5. Participants willing to complete all the study procedures including study-related questionnaires and tasks, and comply with the study requirements.
6. Participants willing to abstain from the restricted supplements and medications prior to inclusion and throughout the study period.
7. Participants with the ability to read and provide written, personally signed, and dated informed consent to participate in the study.

Exclusion Criteria:

1. Known cases of osteo-, rheumatic- or any other form of arthritis.

2. Participants fulfilling ≥ 3 of the following ACR criteria:

   i. Over the age of 50 years ii. Less than 30 minutes of morning stiffness iii. Crepitus on active motion iv. Bony tenderness v. Bony enlargement vi. No palpable warmth at the knee

3. Participants suffering from Insomnia and restless leg syndrome.
4. Participants with uncontrolled Hypertension, as characterized by Systolic Blood Pressure (SBP) >139 mmHg and Diastolic Blood Pressure >89 mmHg.
5. Participants currently on anti-hypertensives
6. Participants suffering from Type II Diabetes Mellitus.
7. Participants with history of lower limb injure in the past six months.
8. Participants currently on joint health supplements and medications.
9. Participants with a history of knee surgery, replacement, or any non-knee surgical procedures that may impact the study outcomes
10. Participants who have used Intraarticular injections in the last six months.
11. Participants who have undergone a significant cardiovascular event in the past six months.
12. Individuals with history of hyperacidity with at least one episode/ week.
13. Individuals with diagnosed cases of migraine.
14. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic, or neurological disorders, that in the judgment of the investigator, would interfere with the participant's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the participant at undue risk.
15. Participants who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put the participant at unacceptable risk for participation in the study or may interfere with evaluations in the study or noncompliance with treatment or visits.
16. Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
17. Participants who have participated in a study of an investigational product 90 days prior to the screening.

18. Participants with heavy alcohol consumption, defined as For men: More than 14 standard alcoholic drink (SAD)/week or more than 4 SAD in a day.

    For women: More than 7 SAD/week or more than 3 SAD in a day.

19. Binge drinkers, defined as 4 or more SAD for women, and 5 or more SAD for men, in a 2-hour time frame.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: E-PR-01 200mg; Oral administration : One capsule to be taken after breakfast and one capsule before dinner for around 5 to 7 days	Other: E-PR-01; Active arm; Other: E- PR-02; Placebo arm
Placebo Comparator: E-PR-02 200mg; Oral administration : One capsule to be taken after breakfast and one capsule before dinner for around 5 to7 days	Other: E-PR-01; Active arm; Other: E- PR-02; Placebo arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Meaningful pain relief assed by Visual Analogue scale	To determine the effect of IP after single dose on time taken to achieve meaningful pain relief as assessed by the time taken to have a reduction of at least 40 % from baseline (0-hour post exertion) on a 100-point pain visual analogue scale as compared to placebo..	From baseline Day 1 for both treatment period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain Intensity Difference (PID)	In this study, the Pain VAS will be used as the method of pain intensity assessment. The values of Pain VAS measured right after IP consumption and each specified time intervals will be the value used to assess PID.at 2-, 3- and 4-hours Day 1 as compared to placebo. Minimum score is 0 represent No pain and 100 means worst possible pain.	At Post IP 2 hour, 3 hour and 4 hours Day 1 of treatment 1 and Post IP 2 hour, 3 hour and 4 hours Day 1 of treatment 2
Sum of Pain Intensity Difference SPID	VAS score will be taken at 0-hour post exertion and at 4 hours post IP consumption after the performance of the modified Naughton Protocol. The summation of the PID values obtained will be used to calculate the sum of Pain Intensity Difference (SPID). Minimum score is 0 represent No pain and 100 means worst possible pain. SPID (ti-ti+n) = ∑ (PIDi)*(ti+1-ti)	at 0-hour post exertion and at 4 hours post IP Day 1 of treatment 1 and 0-hour post exertion and at 4 hours post IP Day 1 of treatment 2

Collaborators and Investigators

• Sponsor: Vedic Lifesciences Pvt. Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 9, 2021
• Primary Completion (Actual): December 15, 2021
• Study Completion (Actual): December 15, 2021

Study Registration Dates

• First Submitted: September 9, 2021
• First Submitted That Met QC Criteria: September 21, 2021
• First Posted (Actual): September 22, 2021

Study Record Updates

• Last Update Posted (Actual): April 6, 2023
• Last Update Submitted That Met QC Criteria: April 3, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Joint Diseases; Musculoskeletal Diseases; Arthralgia
• Other Study ID Numbers: EB/210504/VTZO/JP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No